EU class 3 compression hosiery vs no compression stockings
Adverse effects · people with healed venous leg ulcers
1 finding from 1 review
- no estimate extracted2000 participantsGRADE not reported
Findings
What do systematic reviews say?
4,317 questions · 75,239 findings · 5,342 reviews
No studies found 15,213 · 20.2%GRADE not reported 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
EU class 1 compression hosiery vs EU class 2 compression hosiery
Reulceration · people with healed venous leg ulcers
EU class 1 compression hosiery showed no clear difference in reulceration compared with EU class 2 compression hosiery (low certainty).
1 finding from 1 review
- RR 1.7 [0.67, 4.32]1 study · 99 participantsLow
EU class 1 compression hosiery vs EU class 2 compression hosiery
Duration of reulceration episodes · people with healed venous leg ulcers
1 finding from 1 review
- no estimate extracted2014 participantsGRADE not reported
Methotrexate vs placebo
OutcomesTime frame of absolute effects · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone
Treatment responsea · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone
Sustained clinically inactive diseasec · children and young people with JIA
Oral methotrexate plus intra‐articular glucocorticoid showed no clear difference in sustained clinically inactive diseaseb(12 months) compared with intra‐articular glucocorticoid alone (low certainty).
1 finding from 1 review
- RR 1.37 [0.91, 2.06]1 study · 207 participantsLow
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone
Function · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone
Pain · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone
Global well‐being: rated by participants · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone
Serious adverse events(12 months) · children and young people with JIA
1 finding from 1 review
- no estimate extractedStudies not reportedVery low
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone
Withdrawals due to adverse events · children and young people with JIA
Oral methotrexate plus intra‐articular glucocorticoid showed no clear difference in withdrawals due to adverse events(12 months) compared with intra‐articular glucocorticoid alone (low certainty).
1 finding from 1 review
- RR 8.75 [0.48, 160.4]1 study · 207 participantsLow
Methotrexate vs alternative disease‐modifying antirheumatic drugs
OutcomesTime frame of absolute effects · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Methotrexate vs alternative disease‐modifying antirheumatic drugs
Treatment responsea · children and young people with JIA
Methotrexate showed no clear difference in treatment responsea(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
1 finding from 1 review
- RR 1.4 [0.93, 2.1]1 study · 94 participantsLow
Methotrexate vs alternative disease‐modifying antirheumatic drugs
Sustained clinically inactive diseasec · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Methotrexate vs placebo
Treatment responsea · children and young people with JIA
Methotrexate may leads to higher treatment responsea(up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
- RR 1.67 [1.21, 2.31]3 studies · 328 participantsLow
Methotrexate vs alternative disease‐modifying antirheumatic drugs
Function · children and young people with JIA
1 finding from 1 review
- no estimate extracted1 study · 94 participantsLow
Methotrexate vs alternative disease‐modifying antirheumatic drugs
Pain · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Methotrexate vs alternative disease‐modifying antirheumatic drugs
Global well‐being: rated by participants · children and young people with JIA
1 finding from 1 review
- no estimate extracted1 study · 94 participantsLow
Methotrexate vs alternative disease‐modifying antirheumatic drugs
Serious adverse events(4 months) · children and young people with JIA
Methotrexate showed no clear difference in serious adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
1 finding from 1 review
- RR 0.14 [0.01, 2.69]1 study · 94 participantsLow
Methotrexate vs alternative disease‐modifying antirheumatic drugs
Withdrawals due to adverse events · children and young people with JIA
Methotrexate showed no clear difference in withdrawals due to adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
1 finding from 1 review
- RR 0.33 [0.04, 3.09]1 study · 94 participantsLow